Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP749410.RABVBSQQl3Jy8IdAU7WJ9VnVpg8ugvDRs9cG_ggi0irW0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP749410.RABVBSQQl3Jy8IdAU7WJ9VnVpg8ugvDRs9cG_ggi0irW0130_assertion type Assertion NP749410.RABVBSQQl3Jy8IdAU7WJ9VnVpg8ugvDRs9cG_ggi0irW0130_head.
- NP749410.RABVBSQQl3Jy8IdAU7WJ9VnVpg8ugvDRs9cG_ggi0irW0130_assertion description "[In September 2007, a clinical trial (STEP trial) evaluating the candidate HIV vaccine MRK Ad5 HIV-1 gag/pol/nef from Merck & Co Inc was halted at the first interim analysis because the vaccine demonstrated no positive impact on virus acquisition or virus load following infection.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP749410.RABVBSQQl3Jy8IdAU7WJ9VnVpg8ugvDRs9cG_ggi0irW0130_provenance.
- NP749410.RABVBSQQl3Jy8IdAU7WJ9VnVpg8ugvDRs9cG_ggi0irW0130_assertion evidence source_evidence_literature NP749410.RABVBSQQl3Jy8IdAU7WJ9VnVpg8ugvDRs9cG_ggi0irW0130_provenance.
- NP749410.RABVBSQQl3Jy8IdAU7WJ9VnVpg8ugvDRs9cG_ggi0irW0130_assertion SIO_000772 19579164 NP749410.RABVBSQQl3Jy8IdAU7WJ9VnVpg8ugvDRs9cG_ggi0irW0130_provenance.
- NP749410.RABVBSQQl3Jy8IdAU7WJ9VnVpg8ugvDRs9cG_ggi0irW0130_assertion wasDerivedFrom befree-2016 NP749410.RABVBSQQl3Jy8IdAU7WJ9VnVpg8ugvDRs9cG_ggi0irW0130_provenance.
- NP749410.RABVBSQQl3Jy8IdAU7WJ9VnVpg8ugvDRs9cG_ggi0irW0130_assertion wasGeneratedBy ECO_0000203 NP749410.RABVBSQQl3Jy8IdAU7WJ9VnVpg8ugvDRs9cG_ggi0irW0130_provenance.